University of Toronto research explains how cancer drug Elesclomol works
Research from the University of Toronto, led by Prof. Corey Nislow (Dept. of Molecular Genetics) in collaboration with Synta Pharmaceuticals and published in the scientific journal PLoS ONE, details how the cancer drug Elesclomol targets cancer cell metabolism. The research could lead to safer and more effective cancer therapies with the drug, the molecular workings of which were previously unknown.
